118 related articles for article (PubMed ID: 14650701)
1. Efficacy and safety of rilmenidine, a selective imidazoline I1 receptor binding ligand, in mild-to-moderate Thai hypertensive patients.
Buranakitjaroen P; Kittipawong P; Koanantakul B; Piamsomboon C; Prasassarakich N; Silaraks S; Sukonthasarn A; Tiyapant A;
J Med Assoc Thai; 2003 Oct; 86(10):903-10. PubMed ID: 14650701
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and tolerance of rilmenidine in patients with mild to moderate hypertension. Results of a Czech and Slovak 6-month multicenter study].
Widimský J
Vnitr Lek; 2002 Aug; 48(8):724-9. PubMed ID: 12425202
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of the antihypertensive efficacy of and tolerance to 2 imidazoline receptor agonists: moxonidine and rilmenidine in monotherapy].
Camilleri G; Portal B; Quiniou G; Clerson P
Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):169-74. PubMed ID: 12555509
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome.
Widimský J; Sirotiaková J
Curr Med Res Opin; 2006 Jul; 22(7):1287-94. PubMed ID: 16834827
[TBL] [Abstract][Full Text] [Related]
5. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS).
Farsang C; Lengyel M; Borbás S; Zorándi A; Dienes BS;
Curr Med Res Opin; 2003; 19(3):205-17. PubMed ID: 12803735
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients.
Dupuy O; Bauduceau B; Mayaudon H
Am J Hypertens; 2000 Jun; 13(6 Pt 2):123S-126S. PubMed ID: 10921531
[TBL] [Abstract][Full Text] [Related]
7. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.
Sadowski Z; Szwed H; Kuch-Wocial A; Kubasik A; Januszewicz W; Krupa-Wojciechowska B; Polak G; Stejfa M; Dvorak I; Balazovjech I; Dubai G; Simon K
J Hypertens Suppl; 1998 Aug; 16(3):S55-62. PubMed ID: 9747912
[TBL] [Abstract][Full Text] [Related]
8. [Rilmenidine, a new antihypertensive agent in the first line treatment of essential arterial hypertension. Multicenter double-blind study versus atenolol].
Dallocchio M; Gosse P; Fillastre JP; Grollier G; Morand P; Drici M; Corcoran C
Presse Med; 1991 Aug 31-Sep 7; 20(27):1265-71. PubMed ID: 1832761
[TBL] [Abstract][Full Text] [Related]
9. Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril.
Scemama M; Février B; Beucler I; Dairou F
J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S34-9. PubMed ID: 8642803
[TBL] [Abstract][Full Text] [Related]
10. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
Van Zwieten PA; Peters SL
Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
[TBL] [Abstract][Full Text] [Related]
11. Rilmenidine--its antihypertensive efficacy, safety and impact on quality of life in perimenopausal women with mild to moderate essential hypertension.
Kawecka-Jaszcz K; Czarnecka D; Klocek M; Zabojszcz M; Kucharska M; Jaworski R; Pachocki R
Blood Press; 2006; 15(1):51-8. PubMed ID: 16492616
[TBL] [Abstract][Full Text] [Related]
12. Effects of rilmenidine on 24-h rhythmicity of blood pressure and spontaneous baroreflex sensitivity in essential hypertensive subjects.
Finta E; Laude D; Alföldi S; Farsang C; Elghozi JL
J Hypertens; 2006 Aug; 24(8):1619-25. PubMed ID: 16877965
[TBL] [Abstract][Full Text] [Related]
13. [Effects of rilmenidine (hyperium) on lipid balance in hyperlipidemic hypertensive patients. Randomized, controlled, double-blind 8-week study vs. captopril in parallel groups].
Scemama M; Février B; Beucler I; Dairou F
Ann Cardiol Angeiol (Paris); 1996 Dec; 45(10):595-601. PubMed ID: 9033699
[TBL] [Abstract][Full Text] [Related]
14. Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril.
Bauduceau B; Mayaudon H; Dupuy O
J Cardiovasc Risk; 2000 Feb; 7(1):57-61. PubMed ID: 10785875
[TBL] [Abstract][Full Text] [Related]
15. [Pharmaco-epidemiologic evaluation of rilmenidine in 18,235 hypertensive patients].
Luccioni R
Presse Med; 1995 Dec; 24(38):1857-64. PubMed ID: 8545441
[TBL] [Abstract][Full Text] [Related]
16. Effort blood pressure control in the course of antihypertensive treatment.
de Divitiis O; Di Somma S; Liguori V; Petitto M; Magnotta C; Ausiello M; Natale N; Brignoli M; Galderisi M
Am J Med; 1989 Sep; 87(3C):46S-56S. PubMed ID: 2782327
[TBL] [Abstract][Full Text] [Related]
17. Update on rilmenidine: clinical benefits.
Reid JL
Am J Hypertens; 2001 Nov; 14(11 Pt 2):322S-324S. PubMed ID: 11721891
[TBL] [Abstract][Full Text] [Related]
18. The chronic effect of rilmenidine on heart rate variability in patients with mild hypertension.
Eryonucu B; Ulgen MS; Bilge M; Güler N; Güneş A
Angiology; 2002; 53(2):199-204. PubMed ID: 11952111
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension.
Ostermann G; Brisgand B; Schmitt J; Fillastre JP
Am J Cardiol; 1988 Feb; 61(7):76D-80D. PubMed ID: 2894164
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension.
Panfilov V; Morris AD; Donnelly R; Reid JL
J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S44-7. PubMed ID: 8642805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
